Readership Survey 2007 - Third party
Crafting an international database for retinopathy of prematurity
Intercontinental collaboration is key to unlocking ROP in our lifetime
PHOTON Results and Their Relation to DME Patients in Your Practice
John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.
US FDA approves continuous delivery ranibizumab treatment (Susvimo, Genentech) for diabetic macular oedema
Previously, Susvimo was called the Port Delivery System with ranibizumab in the United States
PULSAR Results and Their Relation to nAMD Patients in Your Practice
John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.
Ocugen, Inc. receives European Medicines Agency ATMP designation for new gene therapy
OCU400 is the first gene therapy from the biotechnology company to move forward into Phase 3 with a broad retinitis pigmentosa (RP) indication
European Medicines Agency CHMP adopts positive opinions for two aflibercept biosimilars
Pavblu and Skojoy, both from Amgen, are indicated for the treatment of neovascular age-related macular degeneration
